These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6356283)

  • 1. Antifungal action of rifampin.
    Medoff G
    Rev Infect Dis; 1983; 5 Suppl 3():S614-9. PubMed ID: 6356283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum.
    Kobbayashi GS; Medoff G; Schlessinger D; Kwan CN; Musser WE
    Science; 1972 Aug; 177(4050):709-10. PubMed ID: 5054147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum.
    Kobayashi GS; Travis S; Medoff G
    Antimicrob Agents Chemother; 1986 Apr; 29(4):660-2. PubMed ID: 3010852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic antifungal activity of pyrrolnitrin.
    Gordee RS; Matthews TR
    Appl Microbiol; 1969 May; 17(5):690-4. PubMed ID: 5785951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampin Enhances the Activity of Amphotericin B against Fusarium solani Species Complex and Aspergillus flavus Species Complex Isolates from Keratitis Patients.
    He Y; Zhou L; Gao C; Han L; Xu Y
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fungistatic and fungicidal effects of amphotericin B, ketoconazole and fluconazole (UK 49,858) against histoplasma capsulatum in vitro and in vivo.
    Polak A; Dixon DM
    Mykosen; 1987 Apr; 30(4):186-94. PubMed ID: 3035371
    [No Abstract]   [Full Text] [Related]  

  • 7. A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil.
    Brilhante RSN; Guedes GMM; Silva MLQD; Castelo-Branco DSCM; Cordeiro RA; Sidrim JJC; Rocha MFG
    Int J Antimicrob Agents; 2018 Aug; 52(2):272-277. PubMed ID: 29592837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy of amphotericin B and rifampicin combined in treatment of murine histoplasmosis and blastomycosis.
    Kitahara M; Kobayashi GS; Medoff G
    J Infect Dis; 1976 Jun; 133(6):663-8. PubMed ID: 932494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergism of amphotericin B and 2-deoxyglucose against Histoplasma capsulatum yeasts in vitro.
    Berliner MD
    Microbios; 1975; 12(50):209-18. PubMed ID: 1160617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
    Perkhofer S; Lugger H; Dierich MP; Lass-Flörl C
    Antimicrob Agents Chemother; 2007 Feb; 51(2):791-3. PubMed ID: 17116665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B.
    Abadi J
    Pediatr Rev; 1995 Oct; 16(10):363-4. PubMed ID: 7479429
    [No Abstract]   [Full Text] [Related]  

  • 12. Rifampin: inhibition of ribonucleic acid synthesis after potentiation by amphotericin B in Saccharomyces cerevisiae.
    Battaner E; Kumar BV
    Antimicrob Agents Chemother; 1974 Apr; 5(4):371-6. PubMed ID: 15825390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro effects of interferon-gamma, alone or in combination with amphotericin B, tested against the pathogenic fungi Candida albicans and Aspergillus fumigatus.
    El-Khoury M; Ligot R; Mahoney S; Stack CM; Perrone GG; Morton CO
    BMC Res Notes; 2017 Aug; 10(1):364. PubMed ID: 28764751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with amphotericin B and caspofungin in an experimental model of disseminated histoplasmosis.
    Rodríguez-Arellanes G; Taylor ML; Pérez-Torres A; Curiel-Quesada E; Vargas-Mendoza CF; Martínez-Rivera MA
    Rev Invest Clin; 2009; 61(1):4-10. PubMed ID: 19507469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endemic mycoses: a treatment update.
    Lortholary O; Denning DW; Dupont B
    J Antimicrob Chemother; 1999 Mar; 43(3):321-31. PubMed ID: 10223586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.
    Sorensen KN; Clemons KV; Stevens DA
    Mycopathologia; 1999; 146(2):53-65. PubMed ID: 10822504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced alterations in the ultrastructural organization of Histoplasma capsulatum and Blastomyces dermatitidis.
    Lane JW; Garrison RG; Johnson DR
    Mycopathol Mycol Appl; 1972 Dec; 48(4):289-96. PubMed ID: 4119289
    [No Abstract]   [Full Text] [Related]  

  • 18. A9145, a new adenine-containing antifungal antibiotic. II. Biological activity.
    Gordee RS; Butler TF
    J Antibiot (Tokyo); 1973 Aug; 26(8):466-70. PubMed ID: 4600794
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of systemic antifungal agents in X-irradiated mice.
    Gordee RS; Matthews TR
    Appl Microbiol; 1970 Oct; 20(4):624-9. PubMed ID: 5498613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of experimental systemic mycoses with BRL 49594A.
    Najvar LK; Luther MF; Graybill JR
    J Antimicrob Chemother; 1995 Dec; 36(6):1005-1011. PubMed ID: 8821599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.